Fosun Tourism Announces 2021 Annual Results : Strong rebound in performance boosted revenue up 30% Accelerate expansion Look forward to the future

Results HighlightsBenefiting from the strong rebound of its businesses in the second half year, the business volume of tourism operations increased by 20% in 2021, with adjusted EBITDA reaching RMB3 million. Both business volume and adjusted EBITDA in the second half year rebounded notably, the business volume of tourism operations rose by 122.1% year-on-year, with adj

Sisram Medical Ltd Announces 2021 Record Annual Results. Strong Performance Led by Synergistic Development of Four Main Business Lines Under One Ecosystem.

Lanvin Group, a Global Luxury Fashion Group, to Become Publicly Traded on the NYSE via Business Combination with Primavera Capital Acquisition Corporation

Wednesday March 23rd, 2022 Lanvin Group is a global luxury fashion group that owns the oldest operating French couture house Lanvin, Italian luxury shoemaker Sergio Rossi, Austrian skinwear specialist Wolford, iconic American womenswear brand St. John Knits, and high-end Italian menswear maker CarusoStrong foundation in Europe combined with a unique position to ca

Fosun Pharma 2021 Annual Results Announcement Accelerating the Globalization Comprehensively The Proportion of Revenue from Innovative Products Continues to Increase

Highlights:Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY;The proportion of revenue from new products as well as regions outside Mainland China and countries overseas continue to increase, continuously optimizing the revenue structure;In 2021, the revenue from new and sub-new products including CO

Fosun Pharma Signs Agreement with The Medicines Patent Pool (MPP) to Produce Low-cost, Generic Version of Pfizer’s Oral COVID-19 Treatment nirmatrelvir In Combination With ritonavir For Supply in 95 Low- and Middle-income Countries

SHANGHAI CHINA, March 18, 2022—Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) announced that Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (“‘Fosun Pharmaceutical Industrial”), a subsidiary company of Fosun Pharma, has signed a sublicense agreement with the Medicines P